ClinicalTrials.gg
CompletedNCT06979388Updated Aug 12, 2025

A Study to Investigate the Effect of Food on Balcinrenone/Dapagliflozin Pharmacokinetics in Fed and Fasted State and Pharmacokinetics of Balcinrenone When Dosed With a P-gp Inhibitor in Healthy Participants.

A Phase 1 interventional study of balcinrenone/ dapagliflozin and quinidine in Healthy Participants, sponsored by AstraZeneca. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-12.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Fasting with a site in United Kingdom — 1 open to participants now, 2 under way, none of them phase 3. Fasting · United Kingdom.

Enrollment
12th of 13
14 · median 54
Started
2025
the only one that year
Phase 1
3 of 14
none open now
Registered
13th of 14
by date
Lead sponsor
2 of 14
AstraZeneca

Among the 14 studies in Fasting with a site in United Kingdom, this one is the 12th largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2025, is one of 3 in phase 1, and was the 13th registered.

Fasting

392 studies on the registry are indexed under Fasting; 63 are open to participants now.

Browse Fasting studies →

Open to participants now

1 of the 14 studies in Fasting with a site in United Kingdom is open now. Recruiting first, the newest first:

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 45 Fasting studies recruiting now, 15 (33%) set no upper age limit and 24 (53%) stop at 75 or younger; 7 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Fasting with a site in United Kingdom, or all of them as a file.
02

Study summary

The main purpose of this study is to assess the effect of food on balcinrenone/ dapagliflozin pharmacokinetics in fed and fasted state and pharmacokinetics of balcinrenone when dosed with a P-gp inhibitor in healthy participants.

Read the detailed description

This study will be an open-label, randomised, 3-period, 3-treatment, single-dose, 3-way crossover study in healthy participants (males and females), performed at a single study site.

The study comprises of:

  • Screening period of 4 weeks within the interval of Day -28 and Day -2.
  • Three treatment periods during which participants will be residing at the Clinical Unit from the day before the first study intervention administration (Day -1). The participant will be discharged on Day 10.

    • Treatment A (reference, fasted), balcinrenone/dapagliflozin capsule dosed in the fasted state.
    • Treatment B (fed), balcinrenone/dapagliflozin capsule dosed together with food.
    • Treatment C (quinidine, fasted), balcinrenone/dapagliflozin capsule (dosed together with a P-gp inhibitor tablets (quinidine) in fasted state.

Participants will be randomised on Day 1 to one of the following 6 treatment sequences: ABC, ACB, BCA, BAC, CAB, or CBA. Each participant will receive all 3 treatments (A, B, and C) in the sequence participant was randomised to. Each treatment will be separated by a washout period of 72 hours; thus, each participant will receive study intervention on Day 1, Day 4, and Day 7.

  • A final Follow-up Call within 5 - 7 days (Day 12-14) after the last study intervention administration.
03

Conditions studied

  • Healthy Participants

Browse trials for

Keywords

  • Food effect
  • Mineralocorticoid receptor modulator
  • P-glycoprotein inhibitor
  • Fed and fasted state
  • Standardised high-fat and high-calorie meal
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Main Inclusion Criteria:

  • Have a (BMI) between 18 and 30 kg/m2 inclusive and weigh at least 50 kg and no more than 100 kg inclusive.
  • All females of must have a negative pregnancy test.
  • Females of childbearing potential must not be lactating and if heterosexually active must agree to use an approved method of highly effective .

Main Exclusion Criteria:

  • History of any disease or disorder which may either put the participant at risk because of participation in the study, or influence the results or the participant's ability to participate in the study
  • History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
  • Any clinically important illness, medical/major surgical procedure, or trauma within 4 weeks of the first administration of study intervention.
  • Any clinically important abnormalities in clinical chemistry, haematology, urinalysis or vital signs.
  • Positive result for serum surface antigen, antibody, and antibody
  • History of long syndrome or history of additional risk factors for QT prolongation - for example a family history of long QT syndrome or the use of concomitant medications known to prolong the QT/QTc interval. Any clinically significant abnormalities on 12-lead at the Screening Visit, as judged by the investigator, including but not limited to any significant arrythmia, conduction abnormalities, and/or prolonged QTcF > 450 ms.
  • Current smokers or those who have smoked or used nicotine products within the previous 3 months prior to Screening Visit.
  • History of alcohol or drug abuse. Positive screen for drugs of abuse, alcohol or cotinine.
  • History of severe allergy/ or ongoing clinically important allergy/hypersensitivity.
  • History of hypersensitivity to drugs with a similar chemical structure or class to balcinrenone, dapagliflozin and quinidine. Any listed for dapagliflozin and quinidine.
  • Use of drugs with enzyme inducing properties within 3 weeks prior to the first administration of study intervention.
  • Use of any prescribed or nonprescribed medication, herbal remedies or intake of > 3 × daily recommended levels of vitamins and minerals during the 2 weeks prior to the first administration of study intervention
  • Plasma donation within one month of screening or any blood donation/blood loss > 500 mL during the 3 months prior to screening.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Treatment ABC

    Participants will receive Treatment A (reference, fasted), balcinrenone/dapagliflozin capsule on Day 1 and then followed by a washout period of 72 hours. On Day 4, participants will receive Treatment B (fed), balcinrenone/dapagliflozin capsule dosed together with food, followed by a washout period of 72 hours. On Day 7, participants will receive Treatment C (quinidine, fasted), balcinrenone/dapagliflozin capsule dosed together with a P-gp inhibitor tablets (2 doses of quinidine separated by 4 hours, 1 hour prior and 3 hours post balcinrenone/dapagliflozin administration, respectively).

    Drug: balcinrenone/ dapagliflozin · Drug: quinidine

  • Experimental
    Treatment ACB

    The participants will receive Treatment A (reference, fasted), balcinrenone/dapagliflozin capsule on Day 1 and then followed by washout period of 72 hours. On Day 4, participants will receive Treatment C (quinidine, fasted), balcinrenone/dapagliflozin capsule dosed together with a P-gp inhibitor tablets (2 doses of quinidine separated by 4 hours, 1 hour prior and 3 hours post balcinrenone/dapagliflozin administration, respectively), followed by a washout period of 72 hours. On Day 7, participants will receive Treatment B (fed), balcinrenone/dapagliflozin capsule dosed together with food.

    Drug: balcinrenone/ dapagliflozin · Drug: quinidine

  • Experimental
    Treatment BCA

    The participants will receive Treatment B (fed), balcinrenone/dapagliflozin capsule dosed together with food on Day 1 and then followed by washout period of 72 hours. On Day 4, participants will receive Treatment C (quinidine, fasted), balcinrenone/dapagliflozin capsule dosed together with a P-gp inhibitor tablets (2 doses of quinidine separated by 4 hours, 1 hour prior and 3 hours post balcinrenone/dapagliflozin administration, respectively), followed by a washout period of 72 hours. On Day 7, participants will receive Treatment A (reference, fasted), balcinrenone/dapagliflozin capsule.

    Drug: balcinrenone/ dapagliflozin · Drug: quinidine

  • Experimental
    Treatment BAC

    The participants will receive Treatment B (fed), balcinrenone/dapagliflozin capsule dosed together with food on Day 1 and then followed by washout period of 72 hours. On Day 4, participants will receive Treatment A (reference, fasted), balcinrenone/dapagliflozin capsule and then followed by washout period of 72 hours. On Day 7 participants will receive Treatment C (quinidine, fasted), balcinrenone/dapagliflozin capsule dosed together with a P-gp inhibitor tablets (2 doses of quinidine separated by 4 hours, 1 hour prior and 3 hours post balcinrenone/dapagliflozin administration, respectively).

    Drug: balcinrenone/ dapagliflozin · Drug: quinidine

  • Experimental
    Treatment CAB

    The participants will receive Treatment C (quinidine, fasted), balcinrenone/dapagliflozin capsule dosed together with a P-gp inhibitor tablets (2 doses of quinidine separated by 4 hours, 1 hour prior and 3 hours post balcinrenone/dapagliflozin administration, respectively), followed by a washout period of 72 hours. On Day 4, participants will receive Treatment A (reference, fasted), balcinrenone/dapagliflozin capsule and then followed by washout period of 72 hours. On Day 7, participants will receive Treatment B (fed), balcinrenone/dapagliflozin capsule dosed together with food.

    Drug: balcinrenone/ dapagliflozin · Drug: quinidine

  • Experimental
    Treatment CBA

    The participants will receive Treatment C (quinidine, fasted), balcinrenone/dapagliflozin capsule dosed together with a P-gp inhibitor tablets (2 doses of quinidine separated by 4 hours, 1 hour prior and 3 hours post balcinrenone/dapagliflozin administration, respectively), followed by a washout period of 72 hours. On Day 4, participants will receive Treatment B (fed), balcinrenone/dapagliflozin capsule dosed together with food, followed by a washout period of 72 hours. On Day 7, participants will receive Treatment A (reference, fasted), balcinrenone/dapagliflozin capsule.

    Drug: balcinrenone/ dapagliflozin · Drug: quinidine

Interventions

  • Drugbalcinrenone/ dapagliflozin

    Drug pages: AZD9977 · Dapagliflozin

    Participants will be receiving balcinrenone/ dapagliflozine in fasted or fed condition.

  • Participants will be receiving quinidine orally in fasted condition.

06

What researchers measure

Primary outcomes

  1. Area under concentration-time curve from time zero to infinity (AUCinf)

    Time frame: From Day 1 to Day 10

  2. Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast)

    Time frame: From Day 1 to Day 10

  3. Maximum observed drug concentration (Cmax)

    Time frame: From Day 1 to Day 10

  4. Terminal elimination half-life (t1/2λz)

    Time frame: From Day 1 to Day 10

  5. Time to reach maximum observed concentration (tmax)

    Time frame: From Day 1 to Day 10

  6. Apparent volume of distribution based on the terminal phase (Vz/F)

    Time frame: From Day 1 to Day 10

  7. Apparent total body clearance (CL/F)

    Time frame: From Day 1 to Day 10

  8. Renal Clearance (CLR) (balcinrenone only)

    Time frame: From Day 1 to Day 10

  9. Drug concentration in plasma at 24 hours post-dose (C24)

    Time frame: From Day 1 to Day 10

Secondary outcomes

  1. Number of participants with adverse events (AEs) and serious adverse events (SAEs)

    Time frame: From Screening (Day -28 to Day -2) until Follow-up (Day 12 to Day 14)

07

Study locations

1 site
  • Research Site
    Harrow, HA1 3UJ, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2025 to primary completion in Jul 2025, 1 month.

Of 18 phase 1 interventional studies under Fasting, half reached primary completion within 1 month of starting (the median), counting those still running; a quarter within 0 and three quarters within 3. This study's 1 month is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2025
First posted
May 19, 2025
StartActual
May 20, 2025
Primary completionActual
Jul 12, 2025
CompletionActual
Jul 12, 2025
Last update
Aug 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06979388
Lead sponsor
AstraZeneca
Collaborators
Parexel
Responsible party
Sponsor
First posted
May 19, 2025
Start date
May 20, 2025
Primary completion
Jul 12, 2025
Completion
Jul 12, 2025
Last update
Aug 12, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: AZD9977 · Dapagliflozin

Start the discussion